Ellen Ypma

2.1k total citations
23 papers, 1.7k citations indexed

About

Ellen Ypma is a scholar working on Epidemiology, Microbiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ellen Ypma has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 18 papers in Microbiology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ellen Ypma's work include Bacterial Infections and Vaccines (18 papers), Pneumonia and Respiratory Infections (17 papers) and Influenza Virus Research Studies (6 papers). Ellen Ypma is often cited by papers focused on Bacterial Infections and Vaccines (18 papers), Pneumonia and Respiratory Infections (17 papers) and Influenza Virus Research Studies (6 papers). Ellen Ypma collaborates with scholars based in Italy, United Kingdom and New Zealand. Ellen Ypma's co-authors include Daniela Toneatto, Audino Podda, Maria Zambon, John Wood, Karl G. Nicholson, Iain Stephenson, Philipp Oster, Peter Dull, Andrew J. Pollard and Matthew D. Snape and has published in prestigious journals such as The Lancet, JAMA and Clinical Infectious Diseases.

In The Last Decade

Ellen Ypma

23 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Ypma Italy	15	1.5k	1.0k	279	254	160	23	1.7k
Annie Vereecken Belgium	24	1.2k 0.8×	977 0.9×	220 0.8×	181 0.7×	82 0.5×	57	2.0k
Daniela Toneatto Italy	25	2.0k 1.4×	2.0k 1.9×	244 0.9×	181 0.7×	10 0.1×	50	2.4k
Pieter G. M. van Gageldonk Netherlands	20	747 0.5×	624 0.6×	204 0.7×	230 0.9×	12 0.1×	41	1.2k
Luwy Musey United States	25	1.3k 0.9×	325 0.3×	743 2.7×	620 2.4×	18 0.1×	62	2.3k
Elizabeth Clutterbuck United Kingdom	19	865 0.6×	420 0.4×	496 1.8×	300 1.2×	10 0.1×	46	1.4k
Hoyam Gamieldien South Africa	17	493 0.3×	476 0.5×	672 2.4×	647 2.5×	26 0.2×	31	1.4k
Alex Vorsters Belgium	27	1.6k 1.1×	223 0.2×	123 0.4×	213 0.8×	23 0.1×	90	1.9k
Pierre Vandepapelière Belgium	23	1.4k 1.0×	166 0.2×	923 3.3×	349 1.4×	18 0.1×	35	2.3k
Karuna P. Karunakaran Canada	19	472 0.3×	647 0.6×	443 1.6×	152 0.6×	76 0.5×	27	1.0k
Mark E. Scott United States	18	772 0.5×	254 0.2×	573 2.1×	76 0.3×	23 0.1×	32	1.3k

Countries citing papers authored by Ellen Ypma

Since Specialization

Citations

This map shows the geographic impact of Ellen Ypma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Ypma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Ypma more than expected).

Fields of papers citing papers by Ellen Ypma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Ypma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Ypma. The network helps show where Ellen Ypma may publish in the future.

Co-authorship network of co-authors of Ellen Ypma

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Ypma. A scholar is included among the top collaborators of Ellen Ypma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Ypma. Ellen Ypma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Prunas, Ottavia, et al.. (2024). Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents. npj Vaccines. 9(1). 239–239. 1 indexed citations

Gasparini, Roberto, Miguel Tregnaghi, Pavitra Keshavan, et al.. (2015). Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. The Pediatric Infectious Disease Journal. 35(1). 81–93. 17 indexed citations

Vesikari, Timo, Susanna Esposito, Roman Prymula, et al.. (2013). Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. The Lancet. 381(9869). 825–835. 209 indexed citations

Finn, Adam, Gianni Bona, Susanna Esposito, et al.. (2012). Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. JAMA. 307. 4 indexed citations

Lennon, Diana, Sui H. Wong, Jing Yan, et al.. (2011). Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Archives of Disease in Childhood. 96(8). 744–751. 21 indexed citations

Toneatto, Daniela, et al.. (2011). The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Human Vaccines. 7(6). 646–653. 71 indexed citations

Toneatto, Daniela, Philipp Oster, George França dos Santos, et al.. (2011). Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Human Vaccines. 7(7). 781–791. 28 indexed citations

Findlow, Jamie, Ray Borrow, Matthew D. Snape, et al.. (2010). Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy. Clinical Infectious Diseases. 51(10). 1127–1137. 226 indexed citations

Snape, Matthew D., Tom Dawson, Philipp Oster, et al.. (2010). Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life. The Pediatric Infectious Disease Journal. 29(11). e71–e79. 159 indexed citations

10.

Lennon, Diana, Catherine Jackson, Joanna Stewart, et al.. (2009). Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine. The Pediatric Infectious Disease Journal. 28(5). 385–390. 28 indexed citations

11.

Jackson, Claire, Diana Lennon, Jing Yan, et al.. (2008). Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Archives of Disease in Childhood. 94(10). 745–751. 21 indexed citations

12.

Schmitt, Heinz-J., Katrin Steul, Astrid Borkowski, et al.. (2008). Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine. 26(18). 2242–2252. 10 indexed citations

13.

Oster, Philipp, Jane O’Hallahan, Ingeborg S. Aaberge, et al.. (2007). Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 25(16). 3075–3079. 62 indexed citations

14.

Martin, Diana, et al.. (2007). Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. Epidemiology and Infection. 136(6). 790–799. 10 indexed citations

15.

Hosking, Jamie, Kumanan Rasanathan, Catherine Jackson, et al.. (2007). Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens. Clinical and Vaccine Immunology. 14(11). 1393–1399. 23 indexed citations

16.

Pollok, M., Helmut Geiger, J. Floege, et al.. (2004). Increased immunogenicity with an MF59-adjuvanted influenza vaccine (FLUAD®) compared with a conventional subunit vaccine (Agrippal®) in renal transplant recipients. International Congress Series. 1263. 453–456. 5 indexed citations

17.

Fumagalli, Luca, et al.. (2003). Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 Immunotherapy. Journal of Immunotherapy. 26(5). 394–402. 77 indexed citations

18.

Stephenson, Iain, Karl G. Nicholson, Audino Podda, et al.. (2003). Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine. 21(15). 1687–1693. 132 indexed citations

19.

Nicholson, Karl G., Audino Podda, Iain Stephenson, et al.. (2001). Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. The Lancet. 357(9272). 1937–1943. 359 indexed citations

20.

Minutello, M, Carla Maria Zotti, Sara Orecchia, et al.. (2000). Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster. Vaccine. 19(1). 10–15. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact